Multi-institutional study of ‘Sandwich treatment’ for motor area large brain metastases (LBM) with diameter over 3 cm
, , , , e
06 gen 2024
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Research Article
Pubblicato online: 06 gen 2024
Pagine: 145 - 152
Ricevuto: 03 lug 2023
Accettato: 23 set 2023
DOI: https://doi.org/10.2478/raon-2024-0002
Parole chiave
© 2024 Zheng Wang et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.

FIGURE 2.

FIGURE 3.

FIGURE 4.

Risk factors of TLC for LBM in motor area after ‘Sandwich treatment’
0.978 | (0.598–1.686) | 0.697 | ||||
>=62 | ||||||
<62 | ||||||
1.678 | (0.913–2.174) | 0.781 | ||||
Male | ||||||
Female | ||||||
Lung/Breast | 0.459 | (0.359–0.898) | < 0.01 | 0.539 | (0.339–0.812) | 0.007 |
Lung/GL tract | 0.913 | (0.478–1.316) | < 0.01 | 0.784 | (0.498–0.987) | 0.006 |
Breast/Gl tract | 1.987 | (0.878–1.974) | 0.411 | |||
2.113 | (1.159–6.733) | 0.139 | ||||
>= 60 | ||||||
<60 | ||||||
0.719 | (0.419–1.598) | 0.211 | ||||
>=20.1cm3 | ||||||
<20.1cm3 | ||||||
1.589 | (0.973–2.894) | 0.566 | ||||
>=12.6cm3 | ||||||
<12.6cm3 | ||||||
1.325 | (0.53–1.734) | 0.989 | ||||
>= 13.0 Gy | ||||||
< 13.0 Gy | ||||||
0.845 | (0.356–1.250) | 0.593 | ||||
>= 12.5 Gy | ||||||
< 12.5 Gy |
Comparison between ‘Sandwich treatment’ and other reports of 2-SSRS strategy for BM
Author | Year | Case number | Median diameter/volume of BM | Total dose | 2-SSRS interval | 6 Months OS/median OS | 6 Months TLC/median TLC | Radiation necrosis |
---|---|---|---|---|---|---|---|---|
Yomo |
2012 | 27 | 17.8 cm3 | 27 Gy | 3−4 weeks | 8.8 months | 89.8% | 11.1% |
Yomo and Hayashi |
2014 | 58 | 16.4 cm3 | 28 Gy | 3−4 weeks | 63% | 85.0% | 8.6% |
Angelov |
2018 | 54 | Diameter>=2cm | 30 Gy | 34 days | 65% | 88.0% | 11.0% |
Dohm |
2018 | 33 | LBM | 29 Gy | 30 days | 65% | 96.8% | 6.06% |
Hori |
2020 | 181 | 4 cm3 | N/A | N/A | 14.6 months | 91.0% | N/A |
Ito |
2020 | 178 | 10 cm3 | 26 Gy | 7−38 days | 6.6 months | 93.2% | 6.20% |
Damron |
2022 | 24 | 8.1 cm3 | 30 Gy | 32 days | 9.1months | 80% | N/A |
Cho |
2022 | 142 | Median 7.4 cm3 | 27−28 Gy | 32 days | 14 months | 88−90% | 17% |
Present study | 2023 | 51 | 20.1 cm3 | 25.5 Gy | 7 days | 91.8%, 14 months | 93.4% | 13.11% |
Patient characteristics
Age(median, years) | 62 | 34–81 |
Sex | ||
Female | 36 | |
Male | 25 | |
Primary tumor | ||
Lung | 39 | |
Breast | 13 | |
Gastric-intestinal tract | 9 | |
KPS (median) | 60 | 50 –80 |
Dose at first-stage SRS (median, Gy) | 13.0 | 11–15 |
Dose at second-stage SRS (median, Gy) | 12.5 | 11–14 |
Total tumor volume (mean, cm3) | 20.1 | 17.2–29.7 |
Peri-tumor edema volume (mean, cm3) | 12.6 | 4.9–19.6 |
Follow-up time (median, months) | 18.3 | 6.3–47.9 |